Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peptide vaccine with or without dacarbazine in high-risk resected melanoma
2008-008211-26Phase 2Active
- Sponsor
- Istituto Superiore di Sanità
- Start
- Jun 2009
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules, Liposomes → Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dacarbazine, melan-a analog peptide, NY-ESO-1b peptide vaccine, interferon alfa-2b and montanide isa-51 in melanoma (2 arms), sponsored by Istituto Superiore di Sanità. Primary endpoint: Distant metastasis-free survival. Started Jun 2009; status: active.
02
Drugs
dacarbazinemelan-a analog peptideNY-ESO-1b peptide vaccineinterferon alfa-2bmontanide isa-51
03
Conditions
melanoma
Beyond the preview
Go deeper on 2008-008211-26.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008211-26.